Pharmacology Pharmacodynamic Mechanisms Questions and Answers 1 — Questions and Answers
Question 1: A partial agonist is administered to a patient who is already taking a full agonist for the same receptor. What is the expected pharmacodynamic effect of adding the partial agonist?
- A synergistic effect, leading to a response greater than the full agonist alone.
- The partial agonist will act as a competitive antagonist, reducing the effect of the full agonist. (Correct answer)
- No change in the overall effect, as the full agonist will completely override the partial agonist.
- An additive effect, where the total response is the sum of the individual effects of both drugs.
Correct answer: The partial agonist will act as a competitive antagonist, reducing the effect of the full agonist.
A partial agonist has affinity for a receptor but lower intrinsic efficacy than a full agonist. When a partial agonist is co-administered with a full agonist, it competes for the same receptor binding sites. By occupying receptors without activating them to the same maximal degree as the full agonist, the partial agonist effectively reduces the number of receptors available for the full agonist, leading to a decrease in the overall therapeutic response. [24, 29]
Question 2: A patient experiences a rapidly diminishing response to a drug after only a few doses administered over a short period. This phenomenon, often due to the depletion of an endogenous substance, is best described as:
- Tolerance
- Tachyphylaxis (Correct answer)
- An idiosyncratic reaction
- Pharmacokinetic antagonism
Correct answer: Tachyphylaxis
Tachyphylaxis is characterized by a rapid decrease in drug response after repeated administration over a short time. [4] It is distinct from tolerance, which typically develops more slowly over days or weeks. A common mechanism for tachyphylaxis is the depletion of neurotransmitters or other endogenous mediators that the drug relies on to produce its effect. [3, 17]
Question 3: Which of the following describes the mechanism of a non-competitive antagonist?
- It binds to the same site as the agonist, and its effect can be overcome by increasing the agonist concentration.
- It produces an effect opposite to that of the agonist by binding to the same receptor.
- It binds to an allosteric site on the receptor, changing the receptor's conformation and preventing agonist activation. (Correct answer)
- It enhances the binding affinity of the agonist for the receptor, leading to an exaggerated response.
Correct answer: It binds to an allosteric site on the receptor, changing the receptor's conformation and preventing agonist activation.
A non-competitive antagonist binds to a site on the receptor that is different from the agonist's binding site (an allosteric site). [2, 9] This binding causes a conformational change in the receptor, which reduces the ability of the agonist to bind or activate the receptor, thereby decreasing the maximal possible effect (Emax). This effect cannot be overcome by simply increasing the concentration of the agonist. [8]
Question 4: A drug is found to decrease the basal activity of a receptor that is constitutively active (active even in the absence of a ligand). This drug is best classified as a(n):
- Full agonist
- Neutral antagonist
- Partial agonist
- Inverse agonist (Correct answer)
Correct answer: Inverse agonist
An inverse agonist binds to the same receptor as an agonist but produces a pharmacological response opposite to that of the agonist. [23] This is possible because some receptors have a baseline (constitutive) level of activity even without an agonist bound. An inverse agonist stabilizes the inactive conformation of the receptor, thus reducing this basal activity and producing an effect opposite to that of a conventional agonist. [6, 23]
Question 5: The activation of a G-protein coupled receptor (GPCR) by an agonist typically initiates a signaling cascade that involves which of the following key steps?
- Direct opening of an ion channel integrated within the receptor structure.
- Binding of the agonist-receptor complex to DNA to alter gene transcription.
- Activation of an intracellular kinase domain that autophosphorylates.
- Exchange of GDP for GTP on the alpha subunit of the associated G-protein. (Correct answer)
Correct answer: Exchange of GDP for GTP on the alpha subunit of the associated G-protein.
Upon agonist binding, a G-protein coupled receptor (GPCR) undergoes a conformational change that allows it to interact with an intracellular heterotrimeric G-protein. This interaction catalyzes the exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) on the G-protein's alpha subunit, leading to its activation and dissociation from the beta-gamma subunit, which then go on to modulate downstream effectors like adenylyl cyclase or phospholipase C. [14, 16]
Question 6: A new drug has a therapeutic index (TI) of 2.0, calculated as the ratio of the TD50 to the ED50. How should this information be interpreted from a clinical safety perspective?
- The drug is extremely safe with a wide margin between effective and toxic doses.
- The drug has a narrow therapeutic window, requiring careful patient monitoring to avoid toxicity. (Correct answer)
- The effective dose is twice the toxic dose, indicating a high risk of therapeutic failure.
- The therapeutic index cannot be used to assess the safety of a drug.
Correct answer: The drug has a narrow therapeutic window, requiring careful patient monitoring to avoid toxicity.
The therapeutic index (TI) is a measure of a drug's safety, calculated as TD50 (median toxic dose) / ED50 (median effective dose). [7, 18] A small or narrow TI, such as 2.0, indicates that the dose required to produce a therapeutic effect is close to the dose that will cause toxicity. [5] Drugs with a narrow therapeutic index require careful dosing and frequent monitoring to ensure plasma concentrations remain within the therapeutic range and to avoid adverse effects. [1, 20]
Pharmacology Pharmacodynamic Mechanisms Questions and Answers 1
A partial agonist is administered to a patient who is already taking a full agonist for the same receptor.
What is the expected pharmacodynamic effect of adding the partial agonist?